In syngeneic mouse models of mammary carcinoma and mesothelioma, significant immune-related antitumor activity of DNA methyltransferase inhibitors was shown when combined with CTLA-4 blockade [30]. This evidence concerns the gene CTLA4 and breast carcinoma.